|Articles|November 30, 2015

Erick Gaussens

Erick Gaussens is Chief Scientific Officer at ProductLife Group

www.productlifegroup.com

egaussens@productlife-group.com

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

Erick Gaussens

Related Content

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel

Preventing Batch Loss: The Growing Role of Preventive and Predictive Maintenance

How AI is Being Implemented Alongside Compliance Concerns

Trending on PharmExec

Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report

FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes

Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals

M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel

M&A Roundup: McKesson to Acquire Precision Medicine Group, Lundbeck & Eversana Enter AI-Powered Partnership